Cellipont and Secretome Join Forces: Advancing cGMP Manufacturing for Innovative Cardiovascular Solutions
Strategic Partnership for Advanced Cell Therapies
Cellipont Bioservices, a prominent player in cell therapy as a Contract Development and Manufacturing Organization (CDMO), has announced an exciting partnership with Secretome Therapeutics, a company focused on developing innovative therapeutics from neonatal cardiac progenitor cells (nCPCs). This collaboration specifically aims at cGMP (Current Good Manufacturing Practice) manufacturing for Secretome's lead asset, STM-01.
Overview of the Collaboration
In this partnership, Cellipont will oversee the transfer of technology and analytical methods, while also providing the necessary cGMP manufacturing capabilities for the STM-01 Master Cell Bank. The novel nCPC product STM-01 has recently gained a composition of matter patent, further solidifying its position in the market, which also includes a related product, STM-21, a secretome-based therapeutic.
Darren Head, the CEO of Cellipont, expressed enthusiasm about the partnership, highlighting the commitment of both companies to address significant unmet medical needs through innovative therapies.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.